KemPharm Inc at JMP Securities Life Sciences Conference (Virtual) Transcript
Thanks again for joining us now this afternoon at the JMP Securities Life Sciences Conference. Next company we have presenting to us is KemPharm. KemPharm is a biopharma company that has a core platform technology that enables prodrugs, and has a couple approved products on the market on the back of that technology, and is now advancing a pipeline as well.
So, with us today is Rich Pascoe, the company's Exec Chairman. So, Rich, turn it over to you. Thanks.
Thank you, Jason. And on behalf of our CEO, Travis Mickle, and the entire team at KemPharm, it's good to be here in person and we appreciate JMP inviting us to share our story.
Before I begin my formal remarks, I'll remind you that we will be making certain forward-looking statements, and I would kindly ask you to refer to our 10-Q and K, which are available on our website, kempharm.com, as well as SEC.gov.
KemPharm is a pharmaceutical company focused on the development, and now
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |